"In an interview with PharmaShots, [Dartmouth Engineering Professor] Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 [the precursor to ADG20] and how it works on SARS-CoV-2," reports the outlet. Select quotes from Gerngross appear below.

..."We are working closely with the regulatory authorities to move ADG20 as quickly as possible through the clinic. We expect ADG20 to enter clinical studies in early 2021. The authorities have also been moving quickly with regard to COVID-19 treatments and vaccines, so it’s our hope we will receive the appropriate designations."

..."Currently we are laser-focused on advancing ADG20 for the treatment and prevention of COVID-19, however, we have good reason to believe it can also be highly effective against multiple other Clade-1 sarbecoviruses."

..."Adagio has been well, and rapidly funded. We raised $130 million in four months. We have aggressive clinical plans for both treatment and prevention settings, so we do expect additional funding and likely we will access the public markets."

..."Currently we are focused on advancing ADG20 for the treatment and prevention of COVID-19. But our scientists have shown an ability to rapidly develop novel antibodies against emerging viruses including SARS, COVID-19, and Ebola. We believe new viruses will continue to emerge, and SARS-like coronaviruses historically have the highest track record of jumping to humans. If ADG-20 can’t address the next pandemic directly, we have high confidence we can rapidly develop an antibody that can."